Gustafsson Ll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2424850/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response. Nature Reviews Drug Discovery, 2011, 10, 495-506.	21.5	293
2	Identification of human cytochrome P 450 s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. European Journal of Clinical Pharmacology, 2003, 59, 429-442.	0.8	213
3	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research, 2010, 10, 153.	0.9	201
4	The â€~Wise List'– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 224-233.	1.2	185
5	4β-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenetics and Genomics, 2008, 18, 201-208.	0.7	132
6	Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 707-722.	0.7	131
7	Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 65-83.	0.7	126
8	SFINX—a drug-drug interaction database designed for clinical decision support systems. European Journal of Clinical Pharmacology, 2009, 65, 627-633.	0.8	124
9	A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict singleâ€dose efavirenz population pharmacokinetics in Ugandans. British Journal of Clinical Pharmacology, 2009, 68, 690-699.	1.1	124
10	Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers*. Clinical Pharmacology and Therapeutics, 1995, 58, 165-173.	2.3	112
11	Malaria Rapid Testing by Community Health Workers Is Effective and Safe for Targeting Malaria Treatment: Randomised Cross-Over Trial in Tanzania. PLoS ONE, 2011, 6, e19753.	1.1	109
12	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	1.3	108
13	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Frontiers in Pharmacology, 2014, 5, 106.	1.6	107
14	Phenotype–genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochemical and Biophysical Research Communications, 2005, 338, 299-305.	1.0	93
15	Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. Frontiers in Pharmacology, 2010, 1, 141.	1.6	90
16	Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. Journal of Comparative Effectiveness Research, 2012, 1, 527-538.	0.6	86
17	Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype*. Clinical Pharmacology and Therapeutics, 1998, 64, 391-401.	2.3	85
18	Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology, 2005, 182, 375-383.	1.5	81

#	Article	IF	CITATIONS
19	High adherence to the †Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open, 2017, 7, e014345.	0.8	81
20	Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infectious Diseases, 2013, 13, 261.	1.3	79
21	Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals, 2010, 3, 2470-2494.	1.7	76
22	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	1.6	75
23	Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology, 2013, 69, 73-78.	0.8	74
24	The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clinical Pharmacology and Therapeutics, 2002, 71, 77-88.	2.3	73
25	Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors*. Clinical Pharmacology and Therapeutics, 1998, 64, 484-491.	2.3	72
26	Impact of training in clinical and microscopy diagnosis of childhood malaria on antimalarial drug prescription and health outcome at primary health care level in Tanzania: A randomized controlled trial. Malaria Journal, 2008, 7, 199.	0.8	71
27	"Quality of prenatal and maternal care: bridging the know-do gap―(QUALMAT study): an electronic clinical decision support system for rural Sub-Saharan Africa. BMC Medical Informatics and Decision Making, 2013, 13, 44.	1.5	69
28	Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 469-479.	0.7	68
29	Enhancing the rational use of new medicines across European health care systems. European Journal of Clinical Pharmacology, 2008, 64, 1137-1138.	0.8	63
30	Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. PLoS ONE, 2014, 9, e86919.	1.1	61
31	Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Research, 2010, 10, 128.	0.9	58
32	Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. Biomedical Applications, 2001, 754, 57-64.	1.7	50
33	Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications. Drugs, 2013, 73, 533-543.	4.9	50
34	Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 608-611.	0.7	49
35	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	0.7	48
36	Metabolism and elimination of quinine in healthy volunteers. European Journal of Clinical Pharmacology, 2003, 59, 423-427.	0.8	44

#	Article	IF	CITATIONS
37	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Frontiers in Pharmacology, 2014, 5, 109.	1.6	44
38	Plasma concentration clamping in the rat using a computer-controlled infusion pump. Pharmaceutical Research, 1992, 09, 800-807.	1.7	43
39	Neonatal Adaptation in Infants Prenatally Exposed to Antidepressants- Clinical Monitoring Using Neonatal Abstinence Score. PLoS ONE, 2014, 9, e111327.	1.1	43
40	High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated <i>Plasmodium falciparum</i> Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. Clinical Infectious Diseases, 2017, 64, 199-206.	2.9	41
41	Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. British Journal of Clinical Pharmacology, 2008, 65, 493-501.	1.1	39
42	The continuing challenge of providing drug information services to diminish the knowledge—practice gap in medical practice. European Journal of Clinical Pharmacology, 2013, 69, 65-72.	0.8	39
43	The roles of cytochrome P450 3A4 and IA2 in the 3-hydroxylation of quinine in vivo. Clinical Pharmacology and Therapeutics, 1999, 66, 454-460.	2.3	38
44	Guidelines for maternal and neonatal "point of care― Needs of and attitudes towards a computerized clinical decision support system in rural Burkina Faso. International Journal of Medical Informatics, 2014, 83, 459-469.	1.6	38
45	Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: A step towards home sampling. Clinical Biochemistry, 2017, 50, 418-424.	0.8	38
46	Adoption of the new antimalarial drug policy in Tanzania - a cross-sectional study in the community. Tropical Medicine and International Health, 2005, 10, 1038-1046.	1.0	37
47	Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region—Bridging the gap between knowledge and practice. International Journal of Medical Informatics, 2007, 76, 497-506.	1.6	37
48	Data extraction from a semi-structured electronic medical record system for outpatients: A model to facilitate the access and use of data for quality control and research. Health Informatics Journal, 2009, 15, 305-319.	1.1	36
49	On the question of dose-dependent chloroquine elimination of a single oral dose. Clinical Pharmacology and Therapeutics, 1983, 34, 383-385.	2.3	35
50	Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1072, 116-122.	1.2	31
51	Whose Job Is It Anyway? Swedish General Practitioners' Perception of Their Responsibility for the Patient's Drug List. Annals of Family Medicine, 2010, 8, 40-46.	0.9	30
52	Continuous intrathecal administration of morphine via an osmotic minipump in the rat. Brain Research, 1982, 247, 195-197.	1.1	29
53	HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects. Clinical Pharmacokinetics, 2011, 50, 531-540.	1.6	29
54	Physicians' reported needs of drug information at point of care in Sweden. British Journal of Clinical Pharmacology, 2012, 73, 115-125.	1.1	29

#	Article	IF	CITATIONS
55	'How to know what you need to do': a cross-country comparison of maternal health guidelines in Burkina Faso, Ghana and Tanzania. Implementation Science, 2012, 7, 31.	2.5	28
56	High-performance liquid chromatographic method for the determination of quinine and 3-hydroxyquinine in blood samples dried on filter paper. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 795, 151-156.	1.2	27
57	Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clinical Pharmacology and Therapeutics, 2000, 68, 189-198.	2.3	25
58	Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European Journal of Clinical Pharmacology, 2006, 62, 539-546.	0.8	25
59	Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 115-124.	0.7	25
60	An Analytical Framework for Assessing Drug and Therapeutics Committee Structure and Work Processes in Tertiary Brazilian Hospitals. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 268-276.	1.2	25
61	Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 3-9.	0.7	24
62	Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden. Applied Health Economics and Health Policy, 2013, 11, 383-393.	1.0	24
63	Drug and therapeutics committees in Nigeria: evaluation of scope and functionality. Expert Review of Clinical Pharmacology, 2018, 11, 1255-1262.	1.3	23
64	Lack of effect of chloroquine on the debrisoquine (CYP2D6) and Sâ€mephenytoin (CYP2C19) hydroxylation phenotypes. British Journal of Clinical Pharmacology, 1996, 41, 344-346.	1.1	22
65	A cross-sectional pilot study assessing needs and attitudes to implementation of Information and Communication Technology for rational use of medicines among healthcare staff in rural Tanzania. BMC Medical Informatics and Decision Making, 2014, 14, 78.	1.5	21
66	The concentration-effect relationship of quinine-induced hearing impairment. Clinical Pharmacology and Therapeutics, 1994, 55, 317-323.	2.3	20
67	Genetic Variations in ABCB1 and CYP3A5 as well as Sex Influence Quinine Disposition Among Ugandans. Therapeutic Drug Monitoring, 2010, 32, 346-352.	1.0	20
68	e‧PC – delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. British Journal of Clinical Pharmacology, 2012, 73, 12-15.	1.1	19
69	Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semiâ€Automatic Methods Using Antiâ€ <scp>TNF</scp> Therapy as Model. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 392-400.	1.2	19
70	Spinal Opioid Analgesia. Drugs, 1988, 35, 597-603.	4.9	18
71	Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects. European Journal of Clinical Pharmacology, 2005, 61, 113-118.	0.8	17
72	A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing. Applied Health Economics and Health Policy, 2013, 11, 79-82.	1.0	17

#	Article	IF	CITATIONS
73	Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee's list of recommended essential medicines (the â€̃Wise List'). European Journal of Clinical Pharmacology, 2018, 74, 131-138.	0.8	17
74	Dried Blood Spot Self-Sampling by Guardians of Children With Epilepsy Is Feasible: Comparison With Plasma for Multiple Antiepileptic Drugs. Therapeutic Drug Monitoring, 2019, 41, 509-518.	1.0	17
75	Nesting doctoral students in collaborative North–South partnerships for health systems research. Global Health Action, 2014, 7, 24070.	0.7	16
76	CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics, 2016, 17, 603-613.	0.6	15
77	A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiology and Drug Safety, 2005, 14, 579-588.	0.9	14
78	Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers. European Journal of Clinical Pharmacology, 2013, 69, 889-899.	0.8	13
79	Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future. Frontiers in Pharmacology, 2012, 3, 198.	1.6	13
80	Quantification of valproic acid in dried blood spots. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 648-652.	0.6	13
81	Rebuilding research capacity in fragile states: the case of a Somali–Swedish global health initiative. Global Health Action, 2017, 10, 1348693.	0.7	13
82	Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS ONE, 2017, 12, e0181316.	1.1	13
83	Determination of melarsoprol in biological fluids by high-performance liquid chromatography and characterisation of two stereoisomers by nuclear magnetic resonance spectroscopy. Biomedical Applications, 1997, 690, 243-251.	1.7	12
84	Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination. Malaria Journal, 2009, 8, 52.	0.8	12
85	Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 402-412.	1.2	12
86	Metabolism is an Important Route of Pentamidine Elimination in the Rat: Disposition of ¹⁴ Câ€Pentamidine and Identification of Metabolites in Urine Using Liquid Chromatographyâ€Tandem Mass Spectrometry. Basic and Clinical Pharmacology and Toxicology, 1995, 77, 114-120.	0.0	11
87	Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France. Applied Health Economics and Health Policy, 2013, 11, 205-218.	1.0	11
88	Drug Information Sources: Reported Preferences By General Practitioners. Drug Information Journal, 1998, 32, 777-785.	0.5	10
89	Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. European Journal of Clinical Pharmacology, 2010, 66, 1229-1234.	0.8	10
90	Development of a computerised decisions support system for renal risk drugs targeting primary healthcare. BMJ Open, 2015, 5, e006775.	0.8	10

#	Article	IF	CITATIONS
91	Comparable Lumefantrine Oral Bioavailability when Coâ€administered With Oilâ€Fortified Maize Porridge or Milk in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2013, 113, 66-72.	1.2	9
92	Concentration–Response Relationship of Hearing Impairment Caused by Quinine and Salicylate: Pharmacological Similarities but Different Molecular Mechanisms. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 5-13.	1.2	9
93	MAGDALENA: study protocol of a randomised, placebo-controlled trial on cognitive development at 2 years of age in children exposed to SSRI in utero. BMJ Open, 2018, 8, e023281.	0.8	9
94	Perceived value of applying Information Communication Technology to implement guidelines in developing countries; an online questionnaire study among public health workers. Online Journal of Public Health Informatics, 2014, 6, e180.	0.4	9
95	Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert Review of Clinical Pharmacology, 2020, 13, 925-934.	1.3	8
96	Opportunities and obstacles using a clinical decision support system for maternal care in Burkina Faso. Online Journal of Public Health Informatics, 2017, 9, e188.	0.4	7
97	Methodological commentary on the analysis of metrifonate and dichlorvos in biological samples. Biomedical Applications, 1993, 612, 336-337.	1.7	6
98	Access to upâ€ŧoâ€date drug information in developing countries continues to pose problems: the case of Uganda. Pharmacoepidemiology and Drug Safety, 2007, 16, 1177-1179.	0.9	6
99	Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability. British Journal of Clinical Pharmacology, 2003, 55, 14-22.	1.1	5
100	Utilization of Analgesics from 1970 to 1978. Acta Medica Scandinavica, 1982, 211, 419-425.	0.0	5
101	The Degree of Analgesia Correlates to Spinal Morphine Concentration after Intrathecal Administration in Rats. Acta Pharmacologica Et Toxicologica, 1986, 58, 243-248.	0.0	5
102	Oilâ€Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 457-465.	1.2	5
103	Pretreatment HIV drug resistance predicts accumulation of new mutations in ARTâ€naÃ⁻ve Ugandan children. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 2706-2716.	0.7	5
104	Liquid chromatography–tandem mass spectrometry applied to a study of the metabolism of pentamidine. Journal of Chromatography A, 1997, 777, 73-79.	1.8	4
105	A study on the state-of-the-art of e-Infrastructures uptake in Africa. Palgrave Communications, 2015, 1,	4.7	4
106	Positron Emission Tomography: An Animal Model of Spinal Distribution of Drugs after Intrathecal Administration. Upsala Journal of Medical Sciences, 1987, 92, 205-213.	0.4	3
107	Reported needs of information resources, research tools, connectivity and infrastructure among African Pharmacological Scientists to improve future patient care and health. Expert Review of Clinical Pharmacology, 2019, 12, 481-489.	1.3	2
108	Parents' perspectives on dried blood spot selfâ€sampling from children with epilepsy: A mixedâ€method study. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 2789-2798.	0.7	2

#	Article	IF	CITATIONS
109	Experiences of patients receiving Home Care and living with polypharmacy: a qualitative interview study. BJGP Open, 2022, 6, BJGPO.2021.0181.	0.9	2
110	"Limit work to here and nowâ€â€"A focus group study on how emergency physicians view their work in relation to patients' drug treatment. International Journal of Qualitative Studies on Health and Well-being, 2008, 3, 155-164.	0.6	1
111	Patients' knowledge and attitudes to the Wise List - a drug formulary from the Stockholm Drug and Therapeutic committee. BMC Health Services Research, 2018, 18, 176.	0.9	0
112	Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2020, 108, 1127-1128.	2.3	0
113	Professor Folke Sjöqvist peacefully passed away on March 30, 2020. European Journal of Clinical Pharmacology, 2020, 76, 1477-1478.	0.8	0
114	ADR databases for onâ€site clinical use: Potentials of summary of products characteristics. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 557-567.	1.2	0
115	MULTIFACETED RESEARCH AND IMPLEMENTING APPROACHES TO CONTROL EMERGING RESISTANCE FOR HIV-, MALARIA- AND TB-THERAPY IN CHILDREN AND PREGNANT WOMEN. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY81-4.	0.0	0
116	An Adverse Drug Reaction Database for Clinical Use – Potential of and Difficulties with the Summary of Product Characteristics. Studies in Health Technology and Informatics, 2022, , .	0.2	0